logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Class
    3. Aminosalicylate

    Aminosalicylate class drugs

    FiltersReset Filters
    4 results

    • lialda

      (mesalamine)
      Takeda Pharmaceuticals America, Inc.
      Usage: LIALDA is indicated for the induction and maintenance of remission in adults with mildly to moderately active ulcerative colitis and for treating mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.

    • mesalamine

      (Mesalamine)
      Chartwell RX, LLC
      Usage: Mesalamine delayed-release tablets are indicated for the induction and maintenance of remission in adults with mildly to moderately active ulcerative colitis. Pediatric usage information exists but is not included on this drug's label due to marketing exclusivity rights.

    • mesalamine

      (mesalamine)
      Ingenus Pharmaceuticals, LLC
      Usage: Mesalamine extended-release capsules are indicated for maintaining remission of ulcerative colitis in adults.

    • mesalamine

      (Mesalamine)
      Upsher-Smith Laboratories, LLC
      Usage: Mesalamine Extended-Release Capsules are indicated for maintaining remission of ulcerative colitis in adults.